Why choose your target tumors early in preclinical stage ?

Published mai 17, 2025

Latest Article

Antibody–Drug Conjugates (ADCs): How Antibody, Linker, and Payload Shape Efficacy and Safety

janvier 13, 2026

Antibody-Drug Conjugates (ADCs) Are Changing Biomarker-Driven Precision Oncology

décembre 13, 2025

Clinical strategy in oncology: rethink animal studies

juillet 30, 2025

Biotome and immunotherapy: a new predictive biomarker?

juillet 28, 2025

FDA’s exemption challenges phase 2 design in oncology. Should we move away from animal models and focus on early, cell-level clinical analysis?

Rethinking phase 2 trials: beyond animal models

juillet 25, 2025

FDA has eased preclinical requirements

juillet 17, 2025

Need Help?

Call Us

P: +41 79 624 79 55

F: +41 21 601 19 38